Skip to content

Study · Systematic review · 2021

5 results

Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials.

Yin DG, Ding LL, Zhou HR, Qiu M, Duan XY

Endocrine journal22 May 2021Cited by 31 (Europe PMC)

PMID34024887 (opens in a new tab)DOI10.1507/endocrj.ej21-0129 (opens in a new tab)PepBankPUB-34024887
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide trials in type 2 diabetes, semaglutide significantly reduced the risk of total serious adverse events versus control.

    In plain wordsIn a pooled analysis of trials in type 2 diabetes, semaglutide led to fewer serious adverse events overall than control.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal serious adverse events
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    RR
    0.92 ratio
    total SAEs

    Source sentences

    Summary
    significantly reduced total SAEs (RR 0.92, 95% CI 0.87-0.97
    2 context sentences
    Summary · context
    Studies eligible for inclusion were the PIONEER and SUSTAIN trials of semaglutide.
    Summary · context
    Twenty-one trials were included.
  2. 02HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide trials in type 2 diabetes, semaglutide significantly reduced the risk of atrial fibrillation versus control.

    In plain wordsIn a pooled analysis of trials in type 2 diabetes, atrial fibrillation was less likely with semaglutide than with control.

    Peptide
    Semaglutide
    Outcome
    DecreaseAtrial fibrillation
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    RR
    0.69 ratio
    atrial fibrillation

    Source sentences

    Summary
    atrial fibrillation (RR 0.69, 95% CI 0.50-0.95
    2 context sentences
    Summary · context
    Studies eligible for inclusion were the PIONEER and SUSTAIN trials of semaglutide.
    Summary · context
    Twenty-one trials were included.
  3. 03HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide trials in type 2 diabetes, semaglutide significantly increased the risk of deep vein thrombosis versus control.

    In plain wordsIn a pooled analysis of trials in type 2 diabetes, deep vein thrombosis was more likely with semaglutide than with control.

    Peptide
    Semaglutide
    Outcome
    IncreaseDeep vein thrombosis
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    RR
    3.66 ratio
    deep vein thrombosis

    Source sentences

    Summary
    deep vein thrombosis (RR 3.66, 95% CI 1.09-12.25
    2 context sentences
    Summary · context
    Studies eligible for inclusion were the PIONEER and SUSTAIN trials of semaglutide.
    Summary · context
    Twenty-one trials were included.
  4. 04HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide trials in type 2 diabetes, semaglutide significantly increased the risk of diarrhoea versus control.

    In plain wordsIn a pooled analysis of trials in type 2 diabetes, diarrhoea was more likely with semaglutide than with control.

    Peptide
    Semaglutide
    Outcome
    IncreaseDiarrhoea
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    RR
    2.66 ratio
    diarrhoea

    Source sentences

    Summary
    diarrhoea (RR 2.66, 95% CI 1.19-5.95
    2 context sentences
    Summary · context
    Studies eligible for inclusion were the PIONEER and SUSTAIN trials of semaglutide.
    Summary · context
    Twenty-one trials were included.
  5. 05HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide trials in type 2 diabetes, semaglutide had no significant effect on 248 other kinds of serious adverse events.

    In plain wordsIn a pooled analysis of trials in type 2 diabetes, semaglutide showed no significant effect on 248 other kinds of serious adverse events.

    Peptide
    Semaglutide
    Outcome
    No significant changeOther serious adverse events (248 kinds)
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide had no significant effects on 248 other kinds of SAEs.
    2 context sentences
    Summary · context
    Studies eligible for inclusion were the PIONEER and SUSTAIN trials of semaglutide.
    Summary · context
    Twenty-one trials were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.